Probable health damage to dogs by intakeing the Bravecto™ Product
Abstract
The product based on fluralaner, brand name Bravecto was launched worldwide in 2014 in the form of a chewable tablet whose action on fleas and ticks lasts around three months. Presented by MSD ANIMAL HEALTH as an innovative product, highly safe, and can be ingested by dogs, including puppies, breeders, pregnant and lactating bitches and Collie dogs. In addition, it is indicated as part of the strategy to control allergic dermatitis and reduce the risk of transmitting fatal diseases transmitted by ticks. However, after its launch, numerous cases of development of pathologies and deaths of dogs of various races and ages, coinciding with the intake of the product began to be reported. Later on, the owners whose dogs had adverse effects on the product were organizing and forwarding reports to the manufacturer and entities responsible for product regulation and marketing and consumer support worldwide such as the CVM's Adverse Drug Event (ADE) EMA (European Medicines Agency), various sites on the pathologies developed in different breeds and the signs presented by the animals in the period of product administration. All this data which have become a database available for consultation.
The European Medicines Agency (EMA) in July 2017 had requested the company to investigate all relevant reports related to various disorders such as neurological, skin and appendage diseases, hypersensitivity or immune-mediated reactions and liver diseases, some of which were fatal. The present review aims to summarize the information and provide a scenario in which, despite the efficacy of the product in the control of ectoparasites, has coincided in the period after its application, with the incidence of several pathologies and even deaths of the canine species.
Keywords
Download Options
Introduction
Fluralaner is a novel, recently developed systemically distributed molecule of the isoxazoline class with a highly selective ectoparasiticidal activity achieved through blocking arthropod gamma-aminobenzoic acid (GABA) and glutamate-ligand gated chloride channels. The mode of action of fluralaner is the antagonism of the ligand-gated chloride channels (gamma-aminobutyric acid (GABA)-receptor and glutamate-receptor).
American regulators, the US Food and Drug Administration (EMA), Canadian, VDD (Veterinary Drugs Directorate) and Brazilian, MAPA (Ministry of Agriculture, Livestock and Food Supply) have approved the registration of Bravecto chewable tablets, from 2014.
MSD Animal Health presented the active ingredient of Bravecto, fluralaner, as a novel, long-acting systemic insecticide and acaricide belonging to the isoxazoline class of parasiticides marketed in the form of a chewable tablet whose action on fleas and ticks lasts around three months. Cited as an innovative, highly safe product, it could be ingested by dogs, including puppies, breeders, pregnant and lactating bitches and Collie dogs. In addition, it is indicated as part of the strategy to control allergic dermatitis and reduce the risk of transmitting fatal diseases transmitted by ticks.
Conclusion
Bravecto product, an insecticide acaracide, based on the fluralaner compound, has it administration coincided to the occurrence of serious pathologies leading to death of dogs in all the countries in which it is in commercialization.
Strong evidences that the product not only targets flea and tick, but compromises the health of the non target species like dogs, its recommendation as oral treatment in the form of chewable tablets, should be carefully reviewed.
